Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Dynavax Technologies Corporation (DVAX - Snapshot Report) suffered a loss of 11 cents per share in the first quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 10 cents per share but flat year over year.

Dynavax reported revenues of $2.1 million, down 11.3% from a year ago but marginally beating the Zacks Consensus Estimate of $2 million.

Collaboration revenues came in at $0.8 million, down 5.0% from the year-ago quarter. Grant revenue from Dynavax’s contract for adjuvant development awarded by the National Institutes of Health declined 30.1% to $0.8 million from the prior year.

Research and development expenses came in at $14.2 million in the first quarter of 2013, up 14.2% driven primarily by the purchase of components for candidate Heplisav along with increase in severance expenses.

General and administrative expenses came in at $8.8 million, a significant jump of 52% from the first quarter of 2012. Incremental severance expenses contributed to the increase.

Dynavax is developing Heplisav, in collaboration with GlaxoSmithKline (GSK - Analyst Report). We note that Heplisav is currently under review in the US and Europe.

In Feb 2013, Dynavax received a setback in its efforts to get the candidate approved in the US. The US Food and Drug Administration (FDA) issued a Complete Response Letter to the company refusing to approve Heplisav in patients in the age group 18-70 without further evaluation of safety.

Dynavax intends to meet the FDA in Jun 2013 to discuss the steps necessary to get the candidate approved. Apart from Heplisav, Dynavax is also developing AZD1419, for the treatment of asthma, in partnership with AstraZeneca (AZN - Analyst Report).

Dynavax carries a Zacks Rank #3 (Hold). Right now, Anika Therapeutics Inc. looks well placed with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
VERTEX ENERG VTNR 8.28 +10.99%
MODINE MANUF MOD 17.19 +9.21%
CLAYTON WILL CWEI 140.21 +7.41%
KNIGHTSBRIDG VLCCF 13.26 +5.70%
CANADIAN SOL CSIQ 30.74 +5.24%